Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir/Dasabuvir plus /- Ribavirin Regimen for Recurrent Genotype 1 HCV Infection After Liver Transplantation - Multicenter, Real-Life, AMBER-CEE Study

被引：0
|
作者：
Tronina, O. [1 ]
Durlik, M. [1 ]
Wawrzynowicz-Syczewska, M. [2 ]
Buivydiene, A. [3 ]
Katzarov, K. [4 ]
Kupcinskas, L. [5 ]
Tolmane, I. [6 ]
Karpinska, E. [2 ]
Pisula, A. [7 ]
Karwowska, K. [8 ]
Bolewska, B. [9 ]
Jablkowski, M. [10 ]
Rostkowska, K. [11 ]
Jakutiene, J. [3 ]
Simonova, M. [4 ]
Flisiak, R. [12 ]
机构：
[1] Med Univ Warsaw, Warsaw, Poland
[2] Pomeranian Med Univ, Szczecin, Poland
[3] Vilnius Univ Hosp, Vilnius, Lithuania
[4] Mil Med Acad, Sofia, Bulgaria
[5] Lithuanian Univ, Kaunas, Lithuania
[6] Latvian State Univ, Fac Med, LV-1063 Riga, Latvia
[7] ID Clin, Myslowice, Poland
[8] Nicholas Copernicus Univ, Coll Med, Bydgoszcz, Poland
[9] Poznan Univ Med Sci, Poznan, Poland
[10] Med Univ Lodz, Lodz, Poland
[11] Wroclaw Med Univ, Wroclaw, Poland
[12] Med Univ Bialystok, Bialystok, Poland
来源：
TRANSPLANTATION | 2016年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
O-41
引用
收藏
页码：S93 / S93
页数：1
相关论文
共 50 条
  • [1] Real-World Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir/ plus Dasabuvir plus /-Ribavirin (OBV/PTV/r/ plus DSV plus /-RBV) Therapy in Recurrent Hepatitis C Virus (HCV) Genotype 1 Infection Post-Liver Transplant: AMBER-CEE Study
    Tronina, Olga
    Durlik, Magdalena
    Wawrzynowicz-Syczewska, Marta
    Buivydiene, Arida
    Katzarov, Krum
    Kupcinskas, Limas
    Tolmane, Ieva
    Karpinska, Ewa
    Pisula, Arkadiusz
    Karwowska, Kornelia Magdalena
    Bolewska, Beata
    Jablkowski, Maciej
    Rostkowska, Karolina
    Jakutiene, Jolita
    Simonova, Marieta
    Flisiak, Robert
    ANNALS OF TRANSPLANTATION, 2017, 22 : 199 - 207
  • [2] Real-world efficacy and safety of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with HCV genotype 1 and 4 infection, final results of the AMBER study
    Flisiak, Robert
    Janczewska, Ewa
    Wawrzynowicz-Syczewska, Marta
    Jaroszewicz, Jerzy
    Zarebska-Michaluk, Dorota
    Nazzal, Khalil
    Bolewska, Beata G.
    Bialkowska, Jolanta
    Berak, Hanna
    Fleischer-Stepniewska, Katarzyna M.
    Tomasiewicz, Krzysztof
    Karwowska, Kornelia
    Rostkowska, Karolina
    Piekarska, Anna
    Tronina, Olga
    Madej, Grzegorz
    Garlicki, Aleksander
    Lucejko, Mariusz
    Pisula, Arkadiusz
    Karpinska, Ewa A.
    Kryczka, Wieslaw
    Wiercinska-Drapalo, Alicia
    Mozer-Lisewska, Iwona
    Jablkowski, Maciej S.
    Horban, Andrzej
    Knysz, Brygida
    Tudrujek, Magdalena
    Halota, Waldemar
    Simon, Krzysztof.
    HEPATOLOGY, 2016, 64 : 987A - 987A
  • [3] Real-life data on the efficacy and safety of ombitasvir/paritaprevir//ritonavir plus dasabuvir plus ribavirin in the patients with genotype 1 chronic hepatitis C virus infection in Serbia
    Babic, Jasmina Simonovic
    Bojovic, Ksenija
    Fabri, Milotka
    Cvejic, Tatjana
    Svorcan, Petar
    Nozic, Darko
    Jovanovic, Maja
    Skrbic, Ranko
    Stojiljkovic, Milos P.
    Mijailovic, Zeljko
    VOJNOSANITETSKI PREGLED, 2019, 76 (05) : 531 - 536
  • [4] REAL LIFE EXPERIENCE WITH OMBITASVIR/PARITAPREVIR/RITONAVIR plus DASABUVIR AND RIBAVIRIN REGIMEN IN PATIENTS WITH COMPENSATED HCV CIRRHOSIS
    Jinga, Mariana
    Balaban, Vasile Daniel
    Ionita-Radu, Florentina
    Costache, Raluca
    Nuta, Petrut
    Bucurica, Sandica
    Popescu, Andrada
    Stoica, Victor
    Vutcanu, Oana
    Milicescu, Mihaela
    Stefan, Ion
    Macadon, Bogdan
    Farcas, Alice
    Naftanaila, Florica
    Alexandru, Aurelia
    Robu, Georgiana C.
    GASTROENTEROLOGY, 2017, 152 (05) : S1148 - S1148
  • [5] Efficacy and safety of paritaprevir/r/ombitasvir/dasabuvir ± ribavirin in genotype 1 HCV infected patients treated in real life settings (AMBER study)
    Flisiak, R.
    Janczewska, E.
    Wawrzynowicz-Syczew, M.
    Wiercinska-Drapalo, A.
    Zarebska-Mich, D.
    Bolewska, B.
    Fleischer-Stepniewska, K.
    Tomasiewic, K.
    Rostkowska, K.
    Karwowska, K.
    Piekarska, A.
    Tronina, O.
    Pisula, A.
    Lucejko, M.
    Karpinska, E.
    Nazzal, K.
    Kryczka, W.
    Mozer-Lisewska, I.
    Knysz, B.
    JOURNAL OF VIRAL HEPATITIS, 2015, 22 : 4 - 4
  • [6] Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis
    Antonio Ascione
    Massimo De Luca
    Mario Melazzini
    Simona Montilla
    Maria Paola Trotta
    Salvatore Petta
    Massimo Puoti
    Vincenzo Sangiovanni
    Vincenzo Messina
    Savino Bruno
    Antonio Izzi
    Erica Villa
    Alessio Aghemo
    Anna Linda Zignego
    Alessandra Orlandini
    Luca Fontanella
    Antonio Gasbarrini
    Marco Marzioni
    Edoardo G. Giannini
    Antonio Craxì
    Infection, 2018, 46 : 607 - 615
  • [7] Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for treatment of recurrent chronic hepatitis C genotype 1 infection after liver transplantation: Real-world experience
    Yu, Ming-Lung
    Chen, Yao-Li
    Huang, Chung-Feng
    Lin, Kuo-Hua
    Yeh, Ming-Lun
    Huang, Ching-I
    Hsieh, Meng-Hsuan
    Lin, Zu-Yau
    Chen, Shinn-Cherng
    Huang, Jee-Fu
    Dai, Chia-Yen
    Chuang, Wan-Long
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2018, 117 (06) : 518 - 526
  • [8] Paritaprevir/ritonavir/ombitasvir plus dasabuvir in HIV/HCV-coinfected patients with genotype 1 in real-life practice
    Pineda, Juan A.
    Rivero-Juarez, Antonio
    de los Santos, Ignacio
    Collado, Antonio
    Merino, Dolores
    Morano-Amado, Luis E.
    Rios, Maria J.
    Perez-Perez, Montserrat
    Tellez, Francisco
    Palacios, Rosario
    Perez, Ana B.
    Mancebo, Maria
    Rivero, Antonio
    Macias, Juan
    HIV CLINICAL TRIALS, 2018, 19 (01): : 23 - 30
  • [9] Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65years with HCV genotype 1 cirrhosis
    Ascione, Antonio
    De Luca, Massimo
    Melazzini, Mario
    Montilla, Simona
    Trotta, Maria Paola
    Petta, Salvatore
    Puoti, Massimo
    Sangiovanni, Vincenzo
    Messina, Vincenzo
    Bruno, Savino
    Izzi, Antonio
    Villa, Erica
    Aghemo, Alessio
    Zignego, Anna Linda
    Orlandini, Alessandra
    Fontanella, Luca
    Gasbarrini, Antonio
    Marzioni, Marco
    Giannini, Edoardo G.
    Craxi, Antonio
    INFECTION, 2018, 46 (05) : 607 - 615
  • [10] SAFETY OF OMBITASVIR/PARITAPREVIR/RITONAVIR plus DASABUVIR IN CHRONIC HEPATITIS C PATIENTS WITH HCV GENOTYPE 1 INFECTION
    Tatara, Tomasz
    Dabrowska-Bender, Marta
    Duda-Zalewska, Aneta
    Staniszewska, Anna
    ACTA POLONIAE PHARMACEUTICA, 2019, 76 (04): : 613 - 619
12345